• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

极早期肝内胆管癌患者相对于治疗方式的生存获益:一项基于国家癌症数据库的分析

Survival Benefit Relative to Treatment Modalities Among Patients with Very Early Intrahepatic Cholangiocarcinoma: an Analysis of the National Cancer Database.

作者信息

Endo Yutaka, Sasaki Kazunari, Munir Muhammad Musaab, Woldesenbet Selamawit, Resende Vivian, Rawicz-Pruszyński Karol, Waqar Usama, Mavani Parit, Katayama Erryk, Yang Jason, Khalil Mujtaba, Khan Muhammad Muntazir Mehdi, Kitago Minoru, Pawlik Timothy M

机构信息

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Department of Surgery, Stanford University, Palo Alto, CA, USA.

出版信息

J Gastrointest Surg. 2023 Oct;27(10):2103-2113. doi: 10.1007/s11605-023-05821-7. Epub 2023 Sep 6.

DOI:10.1007/s11605-023-05821-7
PMID:37674099
Abstract

BACKGROUND

Liver transplantation (LT) has been considered a potential curative treatment for patients with very early intrahepatic cholangiocarcinoma (ICC) and cirrhosis, yet the survival benefit of LT has not been well defined. This study aimed to compare the long-term survival outcomes of patients who underwent LT with that of individuals who received resection and non-curative intent treatment (non-CIT).

METHODS

Patients who underwent LT, hepatectomy, and non-CIT between 2004 and 2018 were included in the National Cancer Database. Survival benefits of LT over resection and non-CIT were analyzed relative to overall survival (OS).

RESULTS

Among 863 patients, 54 (6.3%) underwent LT, while 342 (39.6%) underwent surgical resection, and 467 (54.1%) received non-CIT, respectively. While the rates of non-CIT increased over time, the percentages of LT remained consistent during the study period. LT patients had similar 5-year OS to individuals who underwent resection (referent, resection: LT, HR 0.95, 95%CI 0.84-1.58, p=0.84). In contrast, 5-year OS was better among patients who underwent LT versus individuals who had non-CIT after controlling other variables using propensity score overlapping weighting (5-year OS, LT 57.1% vs. LR 25.8%, p<0.001).

CONCLUSIONS

The outcomes of very early ICC patients who underwent LT were similar to individuals who underwent hepatectomy, but better than patients treated with non-CIT. LT should be may be a consideration as a treatment option for patients with early stage ICC who are unsuitable candidates for resection.

摘要

背景

肝移植(LT)被认为是极早期肝内胆管癌(ICC)合并肝硬化患者的一种潜在治愈性治疗方法,然而LT的生存获益尚未明确界定。本研究旨在比较接受LT的患者与接受手术切除及非根治性意向治疗(非CIT)的患者的长期生存结局。

方法

将2004年至2018年间接受LT、肝切除术及非CIT的患者纳入国家癌症数据库。相对于总生存期(OS),分析LT相对于手术切除和非CIT的生存获益。

结果

在863例患者中,分别有54例(6.3%)接受了LT,342例(39.6%)接受了手术切除,467例(54.1%)接受了非CIT。虽然非CIT的比例随时间增加,但在研究期间LT的比例保持一致。LT患者的5年OS与接受手术切除的患者相似(对照,手术切除:LT,HR 0.95,95%CI 0.84 - 1.58,p = 0.84)。相比之下,在使用倾向评分重叠加权控制其他变量后,接受LT的患者的5年OS优于接受非CIT的患者(5年OS,LT为57.1%,LR为25.8%,p < 0.001)。

结论

接受LT的极早期ICC患者的结局与接受肝切除术的患者相似,但优于接受非CIT治疗的患者。对于不适合手术切除的早期ICC患者,LT可能应被视为一种治疗选择。

相似文献

1
Survival Benefit Relative to Treatment Modalities Among Patients with Very Early Intrahepatic Cholangiocarcinoma: an Analysis of the National Cancer Database.极早期肝内胆管癌患者相对于治疗方式的生存获益:一项基于国家癌症数据库的分析
J Gastrointest Surg. 2023 Oct;27(10):2103-2113. doi: 10.1007/s11605-023-05821-7. Epub 2023 Sep 6.
2
Defining Long-Term Survivors Following Resection of Intrahepatic Cholangiocarcinoma.定义肝内胆管癌切除术后的长期生存者。
J Gastrointest Surg. 2017 Nov;21(11):1888-1897. doi: 10.1007/s11605-017-3550-7. Epub 2017 Aug 24.
3
Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis.肝内胆管细胞癌/肝内胆管癌:它们是肝移植的禁忌证还是适应证?一项倾向评分匹配分析。
Hepatol Int. 2018 Mar;12(2):167-173. doi: 10.1007/s12072-018-9847-0. Epub 2018 Feb 15.
4
Should lymphadenectomy performed routinely in patients with primary intrahepatic cholangiocarcinoma undergoing curative hepatectomy? A retrospective cohort study with propensity-score matching analysis.在接受根治性肝切除的原发性肝内胆管细胞癌患者中,是否应常规进行淋巴结清扫术?一项采用倾向评分匹配分析的回顾性队列研究。
BMC Surg. 2023 Nov 30;23(1):364. doi: 10.1186/s12893-023-02255-5.
5
Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy.肝内胆管细胞癌的围手术期和长期预后:大肝切除与小肝切除的影响。
J Gastrointest Surg. 2017 Nov;21(11):1841-1850. doi: 10.1007/s11605-017-3499-6. Epub 2017 Jul 25.
6
Liver transplantation for intrahepatic cholangiocarcinoma: a propensity score-matched analysis.肝移植治疗肝内胆管细胞癌:一项倾向评分匹配分析。
Sci Rep. 2023 Jun 30;13(1):10630. doi: 10.1038/s41598-023-37896-2.
7
Contemporary trends and outcomes after liver transplantation and resection for intrahepatic cholangiocarcinoma.肝移植和肝内胆管细胞癌切除术的当代趋势和结果。
J Gastrointest Surg. 2024 May;28(5):738-745. doi: 10.1016/j.gassur.2024.02.029. Epub 2024 Feb 22.
8
Parenchyma-preserving hepatectomy in the surgical treatment of hilar cholangiocarcinoma.保留实质的肝切除术在肝门部胆管癌外科治疗中的应用
J Am Coll Surg. 1999 Dec;189(6):575-83. doi: 10.1016/s1072-7515(99)00219-7.
9
Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma involving the hepatic hilus versus hilar cholangiocarcinoma after curative-intent resection: Should they be recognized as perihilar cholangiocarcinoma or differentiated?肝门部胆管癌累及肝门部与肝门部胆管癌根治性切除术后的长期预后和预后因素:是否应将其视为肝门周围胆管癌或加以区分?
Eur J Surg Oncol. 2019 Nov;45(11):2173-2179. doi: 10.1016/j.ejso.2019.06.014. Epub 2019 Jun 11.
10
Development and Validation of a Laboratory Risk Score (LabScore) to Predict Outcomes after Resection for Intrahepatic Cholangiocarcinoma.实验室风险评分(LabScore)的建立与验证:用于预测肝内胆管细胞癌切除术后的结局。
J Am Coll Surg. 2020 Apr;230(4):381-391.e2. doi: 10.1016/j.jamcollsurg.2019.12.025. Epub 2020 Jan 31.

引用本文的文献

1
TRANSMIT: Utilizing discarded livers from donors with a history of cancer for patients lacking access to standard allocation - A compassionate use exploratory study.传递:将有癌症病史的供体废弃肝脏用于无法获得标准分配的患者——一项同情使用探索性研究。
Contemp Clin Trials Commun. 2025 Feb 22;44:101465. doi: 10.1016/j.conctc.2025.101465. eCollection 2025 Apr.

本文引用的文献

1
Cirrhosis in intrahepatic cholangiocarcinoma: prognostic importance and impact on survival.肝内胆管细胞癌中的肝硬化:预后意义及对生存的影响。
BMC Gastroenterol. 2023 May 13;23(1):151. doi: 10.1186/s12876-023-02710-w.
2
A comprehensive preoperative predictive score for post-hepatectomy liver failure after hepatocellular carcinoma resection based on patient comorbidities, tumor burden, and liver function: the CTF score.基于患者合并症、肿瘤负担和肝功能的肝癌切除术后肝衰竭的综合术前预测评分:CTF 评分。
J Gastrointest Surg. 2022 Dec;26(12):2486-2495. doi: 10.1007/s11605-022-05451-5. Epub 2022 Sep 13.
3
Liver transplantation for intrahepatic and hilar cholangiocellular carcinoma: Most recent updates in the literature.
肝内和肝门部胆管细胞癌的肝移植:文献最新进展
Ann Gastroenterol Surg. 2022 Mar 23;6(5):616-622. doi: 10.1002/ags3.12567. eCollection 2022 Sep.
4
Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States.美国早期肝内胆管癌治疗效果的差异。
Cancer. 2022 Oct;128(20):3610-3619. doi: 10.1002/cncr.34436. Epub 2022 Aug 23.
5
Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.日本肝癌研究组肝内胆管癌临床实践指南
Liver Cancer. 2022 Feb 23;11(4):290-314. doi: 10.1159/000522403. eCollection 2022 Jul.
6
Social determinants of health data in solid organ transplantation: National data sources and future directions.社会决定因素在实体器官移植中的健康数据:国家数据来源和未来方向。
Am J Transplant. 2022 Oct;22(10):2293-2301. doi: 10.1111/ajt.17096. Epub 2022 Jun 18.
7
Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis.社会决定因素与肝硬化患者肝移植率的关系。
Hepatology. 2022 Oct;76(4):1079-1089. doi: 10.1002/hep.32469. Epub 2022 Apr 8.
8
Current Barriers to Clinical Liver Xenotransplantation.临床肝异种移植的当前障碍。
Front Immunol. 2022 Feb 23;13:827535. doi: 10.3389/fimmu.2022.827535. eCollection 2022.
9
Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?肝移植治疗肝内胆管细胞癌:是否已经成熟?
Hepatology. 2022 Feb;75(2):455-472. doi: 10.1002/hep.32258. Epub 2022 Jan 6.
10
Incidental intrahepatic cholangiocarcinoma in patients undergoing liver transplantation: A multi-center study in Japan.肝移植患者偶然发生的肝内胆管细胞癌:日本多中心研究。
J Hepatobiliary Pancreat Sci. 2021 Apr;28(4):346-352. doi: 10.1002/jhbp.896. Epub 2021 Feb 9.